Mapping the Clinical Trial Landscape for Cannabinoids in Neurology: A Registry-Based Systematic Review

A systematic review of 47 completed clinical trial registrations on ClinicalTrials.gov reveals that cannabinoid research in neurology has concentrated on Multiple Sclerosis, Fibromyalgia, and Parkinson’s Disease, but the absence of standardized protocols, dosing, and outcome measures across trials remains the central barrier to translating this body of work into defensible clinical guidance.

Why This Matters

Neurological conditions such as Multiple Sclerosis, Parkinson’s Disease, and Fibromyalgia generate enormous patient interest in cannabinoid therapies, often well ahead of the evidence. Clinicians increasingly face questions about THC, CBD, and related compounds for symptom management in these populations, yet the clinical trial base remains fragmented and difficult to interpret. A structured mapping of where trial activity has been concentrated, and where critical gaps persist, provides an essential foundation for informed conversations about what the evidence does and does not yet support.

Clinical Summary

Cannabinoids interact with the endocannabinoid system, which modulates pain signaling, neuroinflammation, and motor function, providing a plausible mechanistic basis for their investigation across a range of neurological conditions. This systematic review, published in 2025, examined clinical trial registrations on ClinicalTrials.gov to characterize the landscape of cannabinoid research in neurology. From an initial pool of over 507,000 registry records, the authors applied multi-step filtering to identify 47 completed trials specifically investigating cannabinoids for neurological disorders. Multiple Sclerosis, Fibromyalgia, and Parkinson’s Disease emerged as the most frequently studied conditions, with most trials conducted at Phase 2 and primary outcomes focused on pain, spasticity, and cognitive function.

The review confirmed that existing regulatory approvals, such as nabiximols (Sativex) for MS-related spasticity and cannabidiol for Dravet and Lennox-Gastaut syndromes, represent the strongest evidence anchor points in this space. However, because the study analyzed trial registrations rather than published results, it could not determine whether individual trials produced positive, negative, or null findings. The authors identified heterogeneous dosing regimens, inconsistent study protocols, and unstandardized outcome measures as the primary barriers preventing synthesis of findings across trials. They concluded that harmonized trial design and reporting standards are needed before the field can move from descriptive mapping to definitive efficacy and safety conclusions.

Dr. Caplan’s Take

This review is useful precisely because it is honest about its limitations. It tells us where the clinical trial machinery has been pointed, not whether the treatments worked. That distinction is critical when patients come in asking whether cannabis can help their MS symptoms or Parkinson’s tremor. What I can tell them is that researchers are actively studying these questions, that a handful of specific products have earned regulatory approval for narrow indications, and that the broader evidence base remains too inconsistent in its methods to draw confident conclusions across conditions.

In practice, I approach cannabinoid discussions with neurological patients by anchoring to the approved indications where evidence is strongest, particularly nabiximols for MS spasticity and pharmaceutical-grade CBD for certain epilepsy syndromes. Beyond those, I am transparent that we are still in an exploratory phase for most neurological applications. I focus on safety screening, drug interaction review, and realistic expectation-setting. I do not discourage interest, but I insist on informed consent that reflects where the science actually stands rather than where patients hope it will arrive.

Clinical Perspective

This review sits very early in the research-to-practice arc. It is a scoping exercise that describes the shape of the trial landscape without evaluating trial quality or synthesizing outcomes. For clinicians, the most actionable insight is negative: the field has not yet produced the kind of standardized, replicable trial evidence that would justify broad clinical adoption of cannabinoids for most neurological indications. The concentration of trials in Phase 2 confirms that even the most-studied conditions remain in intermediate development stages. Clinicians should be cautious about extrapolating from the existence of trial activity to the assumption that efficacy has been demonstrated.

From a pharmacological standpoint, cannabinoid prescribing in neurological populations demands careful attention to drug interactions, particularly with anticonvulsants, dopaminergic agents, and immunomodulatory therapies commonly used in these patient groups. CBD, for example, inhibits CYP3A4 and CYP2C19, which can alter levels of clobazam, valproate, and other medications. THC carries additional considerations around cognitive impairment and psychoactive effects in populations already vulnerable to cognitive decline. The single most practical step clinicians can take now is to ensure that any cannabinoid use in neurological patients is documented, monitored for interactions, and discussed in the context of the specific regulatory approvals that do exist rather than the broader landscape of unfinished research.

Study at a Glance

Study Type

Systematic review of clinical trial registrations (landscape/scoping review)

Data Source

ClinicalTrials.gov registry

Population

Patients with neurological conditions, primarily Multiple Sclerosis, Fibromyalgia, and Parkinson’s Disease

Intervention

Cannabinoid-based therapies, primarily THC and CBD

Comparator

Varied across registered trials; not standardized

Primary Outcomes

Pain, spasticity, cognitive function (as registered); safety and tolerability as secondary outcomes

Initial Records Screened

507,934

Final Included Trials

47 completed registrations

Analysis Type

Descriptive and narrative; no meta-analysis performed

Journal

Published 2025

Funding Source

Not specified in available text

What Kind of Evidence Is This

This is a systematic review of clinical trial registrations, functioning as a landscape or scoping review rather than a traditional systematic review of published results. It occupies a low position in the evidence hierarchy because it analyzes trial metadata, describing intent and design, rather than actual outcomes. The single most important inference constraint is that no efficacy or safety conclusions can be drawn from this type of review, since trial registrations do not report whether interventions succeeded or failed.

How This Fits With the Broader Literature

The review’s descriptive findings align with the existing literature. The concentration of trial activity around MS and epilepsy-related indications reflects the regulatory trajectory already established by nabiximols (approved in multiple countries for MS spasticity) and Epidiolex (FDA-approved for Dravet and Lennox-Gastaut syndromes). The identification of Fibromyalgia and Parkinson’s Disease as emerging areas of trial activity is consistent with growing preclinical and early clinical interest in cannabinoid modulation of pain processing and dopaminergic pathways. However, prior systematic reviews that have analyzed published trial data, such as those by Whiting et al. (2015) and the National Academies of Sciences report (2017), reached similar conclusions about the need for standardization, suggesting that this structural barrier has persisted for nearly a decade without resolution.

Common Misreadings

The most likely overinterpretation is reading the existence of 47 completed trials as evidence that cannabinoids have been shown to work for these neurological conditions. Trial registration tells us that researchers designed and completed studies; it does not tell us what those studies found. The review’s use of language such as “promising results” and “broad therapeutic potential” in its introduction risks amplifying this misreading, but the phrase references previously published data and existing approvals, not new findings generated by this registry analysis. Conflating a map of research activity with a synthesis of research outcomes would significantly overstate what this paper contributes.

Bottom Line

This review provides a structured overview of where cannabinoid clinical trial activity has been concentrated in neurology, confirming that MS, Fibromyalgia, and Parkinson’s Disease are the most-studied conditions and that Phase 2 trials predominate. It does not establish efficacy or safety for any indication. Its most important contribution is documenting the standardization gap that continues to prevent the field from moving toward definitive clinical recommendations. For now, clinical practice should remain anchored to the narrow set of approved indications supported by published trial data.

References

1. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358
2. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. doi:10.17226/24625
3. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011-2020. doi:10.1056/NEJMoa1611618
4. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122-1131. doi:10.1111/j.1468-1331.2010.03328.x